Barely Significant
← all excerpts

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

J Cachexia Sarcopenia Muscle · 2025 · PMC11873539 · PMID 40026058

Europe PMCDOI
1
hedged sentence
0.6355
closest p · 12.7× alpha
0.6355
boldest claim

The sentences

nominally significantp = 0.6355not close (p > 0.1)
In the subgroup with chair stand sub‐score of ≤ 2 in SPPB, the LS mean (SE) difference compared with placebo in CFB to Month 6 was −0.025 (0.053) m/s and 0.090 (0.044) m/s in the 175‐ and 350‐mg BIO101 groups, respectively, statistically nominally significant for the latter ( p = 0.6355 and p = 0.0492, respectively) (Table 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.